 |
|
|
| |
SVR Reduces HCC, decompensated cirrhosis, transplant, death by 50% & more: Projected Long-Term Impact of Vaniprevir (MK-7009) for Previously Treated Chronic HCV Genotype 1 Infection
|
| |
| |
Reported by Jules Levin
APASL - Asian Pacific Association Liver Week
23rd Conference June 6 - 10, 2013, Singapore
from Jules: the importance from this study as I see it is the translation & quantification of SVR, any SVR from any combination therapy into reduced complications from liver-related disease: HCC, decompensated cirrhosis, transplant, death. In this case even though its an estimation from a model reductions in disease are high
Elamin H. Elbasha, Antoine C. El Khoury, Niloufar Mobashery
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
|
| |
|
|
|
|
|
